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Abstract 
Evaluation and quality control of diphtheria and tetanus vaccines have traditionally relied on the use of in vivo protection models 
involving challenge of laboratory animals with toxins. However, for routine lot release, validated serological assays are routinely 
being used that offer significant advantages in terms of reduction in animal numbers because responses to multiple vaccine 
components can be measured in a single group. Use of a serological assay also represents a refinement of procedures since the 
requirement for toxin challenge is removed. The National Institute for Biological Standards and Control (NIBSC, UK) 
contributed to international validation studies on the use of serology for diphtheria and tetanus potency testing, which led to 
revisions of the relevant European Pharmacopoeia method chapters. Here we describe the impact of routine use of a serological 
assay for testing diphtheria and tetanus components of a combined vaccine used for primary immunization of children as part of 
the UK immunization schedule. Opportunities for further reduction in animal numbers are also discussed. 
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1. Introduction 
Diphtheria (D) and tetanus (T) are examples of diseases in which the major clinical manifestations are 
attributable to powerful toxins secreted from the bacteria Corynebacterium diphtheriae or Clostridium tetani, 
respectively. In both cases, circulating antibodies with the ability to bind to and neutralize the toxin are required for 
protection. Diphtheria and tetanus vaccines protect against disease by stimulating production of toxin-neutralizing 
antibodies. They are among the most frequently used vaccines worldwide and have been remarkably successful in 
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reducing the incidence of disease in areas where vaccine coverage is high [1, 2]. These vaccines, manufactured by 
chemical inactivation of D or T toxins (resulting in toxoids), are key components of all childhood immunization 
programs and are also used to boost pre-existing immunity in adolescents and adults. More than 15 different vaccine 
combinations containing D and T toxoids, produced by several manufacturers, are currently licensed in Europe. 
The chemical inactivation of D and T toxin results in toxoids that consist of a heterogeneous population of cross-
linked toxin molecules [3]. Although in vitro antigen detection methods can be used to characterize the final vaccine 
product [4] (which may also contain adjuvant, preservative, other vaccine components, and excipients), the 
confirmation of potency relies heavily on the use of in vivo assays. The potency assays stipulated by the European 
Pharmacopoeia (Ph. Eur.) monographs and World Health Organization (WHO) guidelines involve multiple dilutions 
of a reference and test preparations, and therefore require large numbers of animals to fulfill the requirements of a 
valid assay [5-8]. Potency is expressed relative to a reference vaccine by comparing the quantity of test vaccine 
required to give the same degree of protection as the reference vaccine, which is calibrated in International Units 
(IU). In addition to routine batch release-testing, calibration of new or replacement reference preparations also 
require use of an in vivo protection model [9, 10].  
Serological assays have been considered relevant for routine lot (or batch) release evaluation of DT vaccines 
because the protective response to immunization is antibody mediated, and there are suitable in vitro methods that 
can be used to measure the antibody response in laboratory animals after immunization [11, 12]. The National 
Institute for Biological Standards and Control (NIBSC) contributed to Ph. Eur. collaborative studies on the 
validation of serological methods for DT potency testing [13-16]. The report of a collaborative study published in 
2002 concluded that both the enzyme-linked immunosorbent assay (ELISA) and the toxin-binding inhibition assay 
(ToBI) are suitable for the in vitro analysis of the response to T immunization in the routine lot release of T vaccines 
[13]. Follow-up studies confirmed a correlation between challenge and serological assays for potency testing of D 
vaccines and the relevance of in vitro analysis methods including ELISA and the Vero cell toxin neutralization test. 
These studies also confirmed a suitable dose response for both D and T components in 13 different combination 
vaccine products in the same group of animals [14-16]. Guinea pigs are a suitable animal model for serological 
assays because similar dose-response curves can be obtained for several antigens in combined vaccines [17, 18], 
potentially allowing calculation of the potency of multiple components in the same group of animals. In comparison 
to mice, guinea pigs may be less sensitive to potential interference from adjuvant and other vaccine components 
such as T toxoid conjugated to polysaccharide of Haemophilus influenzae type b [19, 20]. Consequently, the 
likelihood of obtaining a suitable dose response for multiple antigens in a single group of animals is increased. 
Responses in guinea pigs can also be cross-referenced to protection models that have in turn been correlated with 
clinical efficacy [21, 22]. 
The collaborative validation studies led to revision of the relevant Ph. Eur. method chapters for D and T vaccines 
[7, 8] with a recommendation that, in the interest of animal welfare, the serological assay should be used for routine 
batch release after validation for the product to be tested. The process leading to Ph. Eur. acceptance of serological 
methods for DT potency testing took approximately 13 years. Initial recommendations were made in 1994, at a 
European Centre for the Validation of Alternative Methods (ECVAM) workshop, that direct challenge assays used 
for vaccine potency testing should have the highest priority for replacement [23]. After completion of the validation 
studies for D and T vaccines, the revised Ph. Eur. method chapters were adopted by the European Pharmacopoeia 
Commission and subsequently published with an effective date of March 2007. The NIBSC has since introduced the 
serological assay for routine lot release of a pentavalent combined vaccine used in the UK primary immunization 
schedule. In this paper, we report the results of validation studies for this product and the subsequent impact of 
replacing direct challenge assays for D and T potency with a single serological assay for measurement of responses 
to both components.  
2. Material and methods 
2.1. Animal models for measurement of potency of diphtheria and tetanus components 
Protection (challenge) models for measurement of D and T vaccine potency were performed according to the 
methods described in Ph. Eur. Monographs 2.7.6 (Method A, intradermal toxin challenge or Method B, systemic 
challenge) and 2.7.8 (Method A, systemic challenge), respectively [7, 8]. In each case, potency of the test vaccine 
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was calculated against the relevant WHO International Standard. A serological assay using guinea pigs for 
measurement of D and T potency was performed according to the method described in Ph. Eur. Monograph 2.7.6 
(Method C) [7, 8]. 
2.2. ELISA for measurement of diphtheria and tetanus antibody responses 
To measure total IgG antibody responses, NUNC Maxisorb 96-well ELISA plates were coated with 100 µl/well 
of non-adsorbed D toxoid (NIBSC 02/176, 0.5 flocculating units [Lf]/mL) or T toxoid (NIBSC 02/126, 0.5 Lf/mL) 
diluted in sodium carbonate buffer, pH 9.6. Plates were incubated overnight at 4°C and then washed in phosphate-
buffered saline (PBS) containing 0.05% v/v Tween 20 (PBS-T). Plates were then blocked with 150 µl of PBS-T 
containing 5% w/v skimmed milk powder (Marvel) for 1 hour at 37°C. Following a second wash in PBS-T, serial 
twofold dilutions (in PBS-T containing 1% w/v skimmed milk powder) of test serum samples obtained after 
immunization with the test or reference vaccine preparation were prepared down the plate, and the plates were 
incubated at 37°C for 2 hours (final volume 100 µl/well). Plates were washed as described previously, and antigen-
specific IgG antibodies were detected using a horseradish peroxidase-conjugated goat anti-guinea pig IgG antibody 
(Sigma A-7289) diluted 1:2000 in PBS-T containing 1% w/v skimmed milk powder (100 µl/well). After a further 1-
hour incubation at 37°C and a final wash, the chromogen solution containing 0.5 mg/ml ABTS ([2,2’-azino-bis(3-
ethylbenzthiazoline-6-sulfonic acid)]) (Sigma, A-9941) and 0.008% hydrogen peroxide in 0.05 M citrate buffer, pH 
4.0, was added and the reaction was allowed to develop for 30 minutes (100 µl/well). The optical density (OD) was 
measured at 405 nm (A405) by a Multiskan MS ELISA plate reader (ThermoLifeSciences, UK). Antibody responses 
were calculated by parallel-line analysis using CombiStats (Version 4.0, European Directorate for the Quality of 
Medicines and HealthCare [EDQM]) and were expressed in antibody units against an in-house species-specific 
reference serum (NIBSC 98/572).  
2.3. Vero cell assay for measurement of functional diphtheria antibody responses 
Functional D immune responses were determined using the Vero cell toxin neutralization test. The method is 
based on the assay first described by Miyamura and co-workers [24], with modifications to include 
spectrophotometric determination of assay end points [25]. For cell culture, complete medium was prepared using 
minimal essential media (MEM, Sigma M2279) supplemented with calf serum (Invitrogen 10500-064, final 
concentration 5% v/v), L-glutamine (Sigma G7513, 2 mM), D-glucose (Sigma G8644, 0.1% w/v), HEPES (Sigma 
H0887, 0.015 M), and antibiotic/antimycotic solution (Sigma A5955, 1% v/v). Serum samples (100 µl/well) 
obtained after immunization with the test or reference vaccine preparation were added to the first column of a 96-
well tissue culture plate (Falcon), and serial twofold dilutions (50 µl volumes) were prepared across the plate in 
complete medium. Serum samples from all groups were randomly assigned to plates. Purified D toxin (BRP batch 1, 
EDQM) was diluted to 2.5 x 10-5 Lf/mL in complete medium, approximately 4 to 8 times the minimum cytopathic 
dose of toxin for Vero cells in our laboratory. The diluted toxin was added to all wells (50 µl/well) containing serum 
sample dilutions, and the plates were allowed to stand at room temperature for 1 hour to allow neutralization to 
occur.  
A cell suspension containing 4 x 105 Vero cells/mL in complete medium was added to all sample wells 
(50 µl/well). Each plate included control wells containing cells in complete medium only (cell control) or cells in 
complete medium containing D toxin (toxin control). A species-specific reference serum (NIBSC 98/572) was 
included on each plate to allow for plate variation and enable neutralizing antibody titers to be expressed in U/mL. 
The total volume in each well was 150 µl. Plates were incubated for 6 days at +37°C in humidified air containing 
5% CO2. After 6 days, cell viability was determined by incubating cells with Thiazolyl Blue Tetrazolium Bromide 
(MTT). Cells were incubated with MTT (by addition of 10 µl of 5 mg/mL in PBS to all wells) for 4 hours at +37°C 
in humidified air containing 5% CO2. Supernatants were then removed and the MTT–formazan product in viable 
cells was extracted using 10% w/v Sodium Dodecyl Sulfate (SDS) in 50% v/v dimethylformamide, pH 4.7 
(100 µl/well). The plates were returned to the incubator overnight to allow for complete extraction and solubilization 
of the colored product, and the OD was read at 570 nm. The end point for each individual sample was defined as the 
lowest dilution of serum with an OD >50% of the OD for the cell controls on the same plate. End points for all 
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samples (from the test and reference vaccine groups) were converted to titers after accounting for the end point of 
the reference serum on the same plate. End points were expressed in U/mL. 
2.4. Statistical analysis 
The potency of each test vaccine relative to a reference vaccine was calculated by parallel-line bioassay analysis 
comparing transformed assay responses to log vaccine dose [26]. The validity of the fitted model (significant 
regression and no significant nonlinearity or nonparallelism of dose-response lines) was verified before considering 
the potency estimate as valid. For intradermal challenge assays, the squared scores were used as assay responses. In 
systemic challenge assays, a probit transformation of the proportions of animals protected was used. For serological 
assays, the transformed antibody titers were used as assay responses. The choice of transformation is discussed in 
Section 3.4. Variability between potency estimates has been expressed using geometric coefficients of variation 
(GCV = {10s-1}×100%, where s is the standard deviation of the log-transformed potency estimates). The 
significance of any differences between vaccine potencies has been assessed using unpaired two-sided t-test or 
analysis of variance (ANOVA) of log-transformed potency estimates as appropriate. Full details are in the caption 
for Figure 1.  
3. Results 
3.1. Product-specific validation of the serological assay 
Prior to introduction of the serological assay for routine use, the alternative assay was validated for the product 
under test against the appropriate challenge assay following the approach described in the Ph. Eur. [7]. Potency 
estimates obtained in challenge assays were expressed relative to the WHO International Standard for diphtheria or 
tetanus toxoid adsorbed as appropriate. For the serological assay, a batch of the pentavalent product (previously 
released) was calibrated against the relevant WHO International Standard (using the guinea pig challenge assay) and 
designated as a product-specific reference (PSR), with an assigned value in IU. For comparison between different 
assay methods, all potency estimates are shown in relative terms. Diphtheria potency was determined for six lots of 
the combined vaccine by systemic challenge assay (in Laboratory 1), intradermal challenge assay (in Laboratory 2), 
and by serology using ELISA or Vero cell assay for the in vitro analysis of immune responses (Laboratory 2). 
Comparable potency estimates were obtained in all assays (including in vitro analysis by ELISA or Vero cell for the 
serology assay), and there was no significant difference in potency estimates (p=0.13) (Figure 1a). Similarly, T 
potency was determined for the same six lots by systemic challenge assay in guinea pigs (Laboratory 1) and by 
guinea pig serology using ELISA for the in vitro analysis of immune responses (Laboratory 2). Comparable potency 
estimates were obtained in both assays, and there was no significant difference in potency estimates (p=0.51) 
(Figure 1b). These results suggest that the serological assay using ELISA for in vitro analysis of immune responses 
is suitable for routine lot release of this product. 
3.2. Serology assay for routine lot release testing of diphtheria and tetanus components – impact on animal use 
The ability to measure immune responses to more than one component in a combined vaccine using the same 
group of animals has significant implications for reduction in animal use, and the need to perform a separate potency 
test for each component can be removed. An example of the impact in terms of reduction in animal use is shown in 
Figure 2 (based on data from Laboratory 2). The use of a serological assay where the response to immunization is 
measured in vitro after bleeding also represents a refinement of the procedure from severe (systemic toxin 
challenge) or moderate (intradermal or local toxin challenge) to mild (bleed under anesthesia), thus addressing two 
of the three Rs (reduction and refinement). 
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Figure 1. Validation of the serological assay for D and T potency testing of a pentavalent vaccine.  
(a) Diphtheria potency in guinea pigs was determined by challenge assay (systemic challenge in Laboratory 1, n=12 per group and intradermal 
challenge in Laboratory 2, n=8 per group) or serological assay (n=8 per group) using ELISA or Vero cell assay for the in vitro analysis (Laboratory 
2). Challenge assays were performed using the 3rd International Standard for diphtheria toxoid adsorbed (98/560) as the reference vaccine, and 
serology assays were performed using a PSR preparation previously calibrated against 98/560 in the systemic challenge assay in Laboratory 1. All 
potency estimates are shown in relative terms with 95% confidence intervals. ANOVA using log-transformed potency estimates was used to test for 
significant differences between potency estimates obtained in the assay methods (p=0.13).  
(b) Tetanus potency in guinea pigs was determined by systemic challenge assay (n=12 per group) in Laboratory 1 or serological assay with ELISA 
(n=8 per group) in Laboratory 2. The challenge assay was performed using the 3rd International Standard for tetanus toxoid adsorbed (98/552) as 
the reference vaccine, and the serology assay was performed using a PSR preparation previously calibrated against 98/552 in the systemic 
challenge assay in Laboratory 1. All potency estimates are shown in relative terms with 95% confidence intervals. An unpaired t-test using log-
transformed potency estimates was used to test for significant differences between potency estimates obtained in the two assay methods (p=0.51).  
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3.3. Assay precision and variability 
The performance of the serology assay using a PSR in comparison to the traditional challenge test (using the 
WHO International Standard as the reference vaccine) was compared in terms of precision of individual potency 
estimates and the variability of those estimates. Figure 3 shows the precision of individual potency estimates for the 
D component. Potency estimates obtained in the serology assay were consistently precise with no estimates having 
95% confidence limits wider than 50% to 200% (validity requirement for the Ph. Eur. method). This was not the 
case for D potency estimates obtained using the intradermal challenge assay in the same laboratory (Laboratory 2). 
In the intradermal challenge assay, 20% of the batches tested had an upper and/or lower 95% confidence interval 
outside the 50% to 200% limit and would, therefore, be considered invalid according to Ph. Eur. validity 
requirements for this assay. The variability of the potency estimates obtained was also much lower in the serology 
assay (GCV 20%) than in the challenge assay (GCV 49%), suggesting that the serology assay is a superior test for 
routine lot release and monitoring of batch-to-batch consistency.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4. Assay validity 
In addition to potency estimates with unacceptable precision (i.e., confidence intervals wider than 50% to 200%), 
significant nonlinearity of the vaccine dose response and/or nonparallelism of the dose response between the 
reference and test vaccine may lead to invalidity. Data from routine lot release testing using the intradermal 
challenge assay in Laboratory 2 showed that 27% of individual estimates were invalid at the 1% significance level 
(n=67) compared to 18% of estimates obtained after introduction of the serological assay (n=57).  
Analysis of all data obtained in the D serology assay revealed that the choice of transformation model used can 
have a dramatic effect on the validity of the potency estimates obtained. Typically, a log transformation of the 
antibody titers is used in the parallel-line analysis calculation of relative potency from serological assays. All data 
were re-analysed using a square root transformation. For the same data set, only 2 of 57 estimates (4%) were invalid 
at the 1% level of significance (Table 1). For each assay, the assumptions of homogeneity of variance across 
treatment groups and normality within treatment groups were also assessed for both transformation models using 
Bartlett’s test to detect heterogeneity of variance and Shapiro-Wilk test for non-normality. The results indicated that 
Figure 2. Reduction in animal use for D and T potency testing by use of the serological method.  
Data are the total number of animals required to determine the potency of D and T components in a combined vaccine product using 
challenge or serological assays (in Laboratory 2). Figures are based on a single challenge assay for D potency in guinea pigs (3 dilutions, n=8 
per group) and a single assay for T potency in mice (4 dilutions, n=16 per group) compared to a single serology assay in guinea pigs (3 
dilutions, n=8 per group) for both components. In each case, the total number of guinea pigs (black bars) and mice (shaded bars) required to 
test two vaccine lots against a reference preparation is shown. 
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the use of a square root transformation provided better agreement with the assumptions underlying the parallel-line 
model analysis for this assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.5. Opportunities for further reduction in animal use 
3.5.1. Single-dilution approach (reduction in number of vaccine doses)  
Potency assays performed according to the WHO or Ph. Eur. recommendations are typically multiple-dilution 
assays that allow for an estimate of vaccine potency to be obtained in IU. These assays are required for licensing and 
during early stages of lot release, although once consistency in production has been demonstrated and the test 
operator has gained sufficient experience in testing the product in question, the procedure can be modified to include 
only a single dilution of the reference preparation and vaccine under test (this applies to challenge and serological 
methods). This does not allow for a point estimate of vaccine potency to be obtained but can be used to demonstrate 
that the vaccine potency exceeds a certain level and thereby meets the minimum requirement for that component. In 
order for the single-dilution approach to be adopted, the measured potency of the component under test must be 
shown to be consistently higher than the minimum requirement for that product. In addition, a significant regression 
of the dose response and parallelism between the reference and test vaccine must be demonstrated (from historical 
data obtained using the multiple-dilution assay). 
A single-dilution approach has been implemented for the measurement of T potency as part of routine lot release 
testing because the potency of this component has been demonstrated to be consistently above the minimum 
requirement of 40 IU per single human dose (SHD), and the requirements for a valid dose-response have also been 
demonstrated (not shown). The assay design for single-dilution potency testing depends in part on the assigned 
potency of the reference vaccine and also the dilution scheme employed in the assay [27]. In this case, the PSR has 
an assigned T potency of 224 IU/SHD, and the dilutions of reference and test vaccine used (1/5, 1/15, 1/45) have 
been selected to provide the optimal dose response for calculation of potency for both D and T components (in the 
Figure 3. Precision of diphtheria potency estimates obtained in challenge and serology assays. Data (from Laboratory 2) are the lower 
and upper 95% confidence interval for D potency estimates expressed as a percentage of the estimate. All estimates (n=41 for both methods) 
are from unique vaccine lots obtained using either intradermal challenge or serology in guinea pigs (n=8 per group) with ELISA for in vitro 
analysis in the serology assay. Challenge assays were performed using the 3rd International Standard for diphtheria toxoid adsorbed (98/560) 
as the reference vaccine, and serology assays were performed using a PSR preparation previously calibrated against 98/560 as described in 
the caption for Figure 1. The Ph. Eur. definition of a valid potency estimate is one in which the 95% confidence intervals are between 50% 
and 200% of the mean estimate, and these specification limits are indicated by a solid line. 
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multiple-dilution assay). Because the 1/15 dilution of the PSR contains 15 IU/SHD, an assumption is made that the 
test vaccine contains 75 IU/SHD when undiluted (which exceeds the minimum requirement of 40 IU/SHD) and, 
therefore, will contain 15 IU/SHD when diluted 1/5. If the mean log antibody titer in the test vaccine group (1/5) is 
higher than that in the matched reference vaccine group (1/15), log titers are compared using an unpaired one-tailed 
t-test. When a significant difference is detected, the potency of the test vaccine is concluded to be significantly 
higher than 75 IU/SHD (and, therefore, significantly higher than the minimum requirement of 40 IU/SHD). An 
example of the data analysis for the T single-dilution assay is shown in Figure 4. 
 
Table 1. Effect of transformation model on serology assay validity. 
Parallel-line analysis for D vaccine potency was performed using a log transformation or square root transformation of individual 
antibody responses (n=8 per group). The table shows the number (and %) of D potency estimates (n=57) showing significant 
deviations from parallel-line model assumptions. 
 
 
Significance level 
Potency Estimates with Significant Deviation from Parallel-line Model 
Assumptions (n=57) 
 Log transformation Square root transformation 
Nonlinearity or  
nonparallelism 
p<0.05 30 (53%) 5 (9%) 
p<0.01 10 (18%) 2 (4%) 
Heterogeneity of variance p<0.05 23 (40%) 13 (23%) 
p<0.01 11 (19%) 5 (9%) 
Non-normality p<0.05 4 (7%) 5 (9%) 
p<0.01 1 (2%) 2 (4%) 
 
3.5.2. Reduction in number of animals per vaccine dose  
The single-dilution approach is not applicable for testing of all products—for example, where the potency for a 
particular component is close to the minimum requirement. However, where multiple dilution assays are performed, 
it may be possible to reduce the number of animals used per vaccine dose without compromising the outcome of the 
potency test. In many cases, legacy data can be used to provide information on the suitability of sample group size 
for a particular assay. The data obtained using the serology assay for D potency in Laboratory 2 has been reviewed 
to provide such information. The relative potency of all lots previously tested was recalculated such that relative 
potency estimates were obtained with group sizes ranging from 2 to 8. A total of 60 lots were included in the 
analysis, and the relative potency measured was unaffected by a change in the group size (not shown), although the 
precision of the estimates was inversely proportional to the group size (Figure 5).  
4. Discussion 
A serological assay for potency testing of D and T components in a combined vaccine was validated for routine 
lot release of a pentavalent combined vaccine. Potency estimates were obtained using conventional protection assays 
and compared to estimates obtained using the serological assay. No significant differences in D or T potency were 
detected using the different assay systems. The results also confirmed that, for the product under test, serology with 
ELISA for in vitro analysis produced comparable results to serology with Vero cell assay for the in vitro part of the 
test (for the D component). For the comparison between challenge and serology for measurement of T potency, the 
results obtained in a challenge assay from Laboratory 1 (for the same vaccine lots) were used because the test was 
performed using the same species of animal (guinea pigs). Furthermore, the PSR used in the serology assay was 
calibrated in Laboratory 1 in the guinea pig challenge assay. As a result, it was appropriate to use data from this 
assay for comparison with serology results obtained by Laboratory 2. For consistency, the results of D potency 
estimates obtained in the challenge assay from the two laboratories were also included and shown to be comparable 
to results of the serological assay.  
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The results agree with the findings of the Ph. Eur. collaborative validation studies. In the T vaccine study, six 
laboratories evaluated between five and seven vaccines containing T component and obtained comparable potency 
estimates (relative to a common reference vaccine) in the challenge assay and serological assay [13]. Animals were 
bled two days before toxin challenge, and the study also confirmed a relationship between the mean antitoxin 
concentration (determined either by ELISA or ToBI) and survival after challenge. In the D study, seven laboratories 
tested five different products containing D component and confirmed similar rankings of the vaccines in all assays 
(challenge and serology using ELISA and Vero cell assay), the only exception being an inversion of the ranking in 
some laboratories between two of the products which had almost identical D potency as reported by the vaccine 
manufacturer [14]. Because of the results obtained from in-house validation testing for the pentavalent product 
shown in this paper and the conclusions from the earlier collaborative validation studies, ELISA was chosen for the 
in vitro assessment of anti-D and anti-T antibody responses in routine use of the serological assay for this product. 
Data from routine in-house testing has also confirmed that the ELISA is a more precise assay than the Vero cell 
assay for measurement of anti-D responses (not shown).  
These earlier collaborative validation studies also showed that differences in antitoxin titers obtained in the in 
vitro assay (for example, as a result of different reference sera being used) do not have an impact on the final 
potency calculation because potency is expressed relative to a reference vaccine in all cases. In-house monitoring of 
functional D antibody responses in guinea pigs immunized with the pentavalent vaccine product have revealed that 
the response may be significantly different in animals of the same strain that were obtained from two different 
suppliers (Figure 6). The same observation was also made for total anti-D responses and anti-T responses measured 
by ELISA (not shown). However, this has no impact on vaccine potency because antibody responses from the test 
and reference vaccine are equally affected, and potency is expressed in relative terms. Such observations may be 
more relevant for potency tests (such as the U.S. National Institutes of Health test for D and T potency), which do 
not rely on the use of a reference vaccine for expression of relative potency.   
The introduction of the serological method has significantly reduced the number of animals required for D and T 
potency testing. Because the same group of animals is used to measure D and T responses, the requirement to 
perform a separate assay for each component is removed and a separate challenge assay for T potency is no longer 
required for lot release of this product in Laboratory 1 or 2. In addition, the requirement for toxin challenge has been  
Figure 4. Example of the single-dilution approach for potency of tetanus component. 
Data (from Laboratory 2) are the log-transformed anti-T antibody responses from guinea pigs (n=8 per group) immunized with the PSR 
vaccine (at 1/15 dilution) or test vaccine (at 1/5 dilution). Assuming the mean log antibody titer in the test vaccine group is higher than that in 
the matched reference vaccine group, log titers are compared using an unpaired one-tailed t-test. In this example, the response in the test 
vaccine group is significantly higher than the response in the reference vaccine group (p<0.05), and the conclusion is made that the test 
vaccine potency exceeds 75 IU/SHD.  
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removed completely, which offers significant benefits in animal welfare in terms of refinement of the procedure. 
This also has safety advantages for operators because they no longer need to handle toxin for preparation of 
challenge dilutions and injection. Although mice can be used for potency testing of both D and T components in 
combined vaccines, guinea pigs are a superior model for serological assays. The major benefit of the serological 
assay, in terms of reduction in animal use, arises from the ability to assess the immune response to multiple 
components in the same vaccine. The response to certain vaccine components (most notably T) in mice depends on 
the strain used [9, 28] and is heavily influenced by the presence of other components such as T toxoid 
polysaccharide conjugates [19, 20]. As a result, there may be a large disparity in the level of the immune response of 
mice to different antigens in a combined vaccine, such that single groups of animals immunized with the same 
vaccine dilution scheme could not be used effectively to measure responses to multiple components. However, it 
should also be noted that many countries experience problems obtaining and maintaining a supply of guinea pigs, 
meaning that widespread adoption of guinea pig serology might be difficult to achieve. 
Figure 5. Effect of group size on precision of diphtheria potency estimates in the serology assay.  
Data (from Laboratory 2) are the lower (a) or upper (b) 95% confidence intervals expressed as a percentage of the estimate for 60 different lots of 
the pentavalent combined vaccine product. The Ph. Eur. definition of a valid potency estimate is one in which the 95% confidence intervals are 
between 50% and 200% of the mean estimate, and these specification limits are indicated by a solid line at 50% (a) and 200% (b). 
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In many cases, use of a serological assay will require a PSR preparation calibrated in IU against the relevant 
WHO International Standard. This is important to allow measurement of responses to multiple components in the 
test vaccine without the need to include separate groups of animals for each individual reference preparation, 
thereby maximizing the reduction in animal use. The use of a PSR may also lead to improved assay performance in 
terms of precision and variability of potency estimates and a reduction in the number of invalid assays caused by 
non-parallelism between the reference and test preparation. When testing multivalent combined vaccine products, 
there is potential for significant qualitative differences between the reference preparation and the product under test, 
particularly where the reference vaccine consists of a monovalent or divalent preparation. This may exacerbate the 
relatively poor precision of inherently variable in vivo potency assays. Qualitative differences between a reference 
and test vaccine are reflected in the relative potency estimate and this may be influenced by changes in technical 
performance of the assay (for example, extent of dilution, operator, injection site), possibly leading to a lack of 
harmonization of potency estimates between laboratories (unpublished observations). When a PSR preparation is 
included in the potency assay the impact of any changes in the technical performance of an assay will be minimized 
(since both the product under test and PSR are likely to be affected to the same extent). Diphtheria potency estimates 
obtained using serology in Laboratory 2 were shown to be consistently precise (as defined by 95% confidence 
intervals within 50% to 200% of the estimate), which was not the case for estimates obtained in the challenge assay. 
The variability (GCV) of serology D potency estimates between different batches of the product was less than half 
that of estimates obtained in the challenge assay. This is important for control testing because one of the primary 
functions is to be able to monitor consistency of production and identify “true” differences between lots. An assay 
with low variability is, therefore, more suitable for this purpose.  
Vaccine potency assays in which in vivo responses are expressed relative to a reference vaccine may also be 
subject to high rates of invalidity due to nonlinearity of the dose response and/or nonparallelism between the 
reference and test vaccine preparations. In the intradermal challenge assay used for measurement of D potency, 27% 
of estimates were invalid at the 1% significance level. This was reduced to 18% for D serology assays. In the 
serological assay, no cases of invalidity were caused by nonparallelism, which might be expected because there 
should be no significant qualitative difference between the test product and the PSR preparation. The use of a PSR 
in the serological assay is likely to be a major factor in the improved precision, variability, and validity of the D 
potency estimates obtained in Laboratory 2, and it fulfills the underlying principle of biological standardization that 
like is compared with like. 
Figure 6. Effect of animal supplier on functional diphtheria responses. 
Data (from Laboratory 2) are the anti-D toxin neutralizing antibody concentrations in U/mL with 95% confidence intervals (determined by 
Vero cell assay). Results are the geometric mean from seven assays (n=8 per group) from each of two different animal suppliers. An unpaired 
t-test on log-transformed antibody titers was used to compare responses at each vaccine dilution (p<0.001 at each vaccine dilution). 
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A review of all data obtained using the serology assay since its introduction revealed that the choice of 
transformation model used in the parallel-line analysis can have a dramatic impact on rates of invalidity. Analysis 
using a square root transformation of the antibody responses has now been implemented by Laboratory 2, and the 
data suggest that only 4% of estimates will be invalid (compared to 18% using a log transformation and the same 
level of significance). This has implications for reduction of animal use because there is a reduced requirement to 
perform repeat testing. This is a good example of the use of legacy data to assess assay performance and identify 
areas that can be modified in order to improve performance, which can ultimately have an impact on animal use. A 
more direct example is review of data to assess the relevance of group size in terms of generating results that meet 
the precision requirements for a valid assay. It is clear that for most assays there is a maximum group size beyond 
which no benefit is obtained in terms of obtaining a valid result. Validation of alternative methods leading to long-
term reduction in animal use often requires an initial increase in animal numbers to demonstrate equivalence 
between two methods. The review of legacy data presented here is an example of work that can be undertaken with 
no additional requirement for animal use that can still lead to long-term reductions in animal use. 
One of the major opportunities to reduce animal numbers required for WHO/Ph. Eur. D and T potency assays is 
the use of a single-dilution approach that requires only one dilution each of the reference and test vaccine 
preparations [6-8, 27]. For the serological assay described in this paper, a single-dilution approach for both D and T 
components would reduce by 78% the number of animals needed to release two vaccine lots. When used as part of a 
challenge model, the single-dilution approach does not allow for a point estimate of vaccine potency to be obtained 
but simply provides evidence that the test vaccine meets (or surpasses) the minimum requirement for potency of that 
particular component. Where this approach is used, it is not possible to monitor consistency in production or identify 
trends because no quantitative data are returned. In addition to the benefits already discussed, another advantage of 
the serological assay compared to the challenge test is that use of a single-dilution approach does allow for some 
degree of monitoring between different lots because quantitative data are generated by measuring the antibody 
responses in vitro. As a result, the assay can be monitored by following the geometric mean antibody response to the 
reference vaccine, and the consistency of production can be monitored by following the geometric mean antibody 
response of different vaccine lots. It is not possible to apply the single-dilution approach to all components in all 
products, for example, where the potency of a particular component is close to the minimum requirement. However, 
when testing certain products in which the single-dilution model can be applied to all components, the reduction in 
animal use achieved by serological assessment of antibody responses to multiple components can be maximized.  
Introduction of the serological assay for DT potency testing has significantly reduced the number of animals 
required for routine lot release of a key vaccine used in the UK primary immunization schedule. The requirement for 
toxin challenge has been removed as has the need to perform a separate potency test in mice for the tetanus 
component. For diphtheria potency, the assay precision and variability is superior to that seen with the challenge 
model used previously, and the number of invalid assays was also reduced. The implementation of an alternative 
transformation model used in the analysis for potency calculation is expected to lead to even fewer invalid estimates 
for D potency in the future. A single dilution approach has been successfully applied for the tetanus component, and 
analysis of immune responses in vitro allows consistency of production to be monitored. Once validated, the 
serological assay may be a superior batch release test and should be considered for all products for the assessment of 
vaccine components where protection is antibody mediated. 
References 
[1] Borrow R, Balmer P, Roper MH. The immunological basis for immunization series. Module 3: Tetanus update 2006. Immunization, 
Vaccines and Biologicals. Geneva: World Health Organization, 2007. Available at: www.who.int/vaccines-
documents/DocsPDF07/869.pdf   
[2] Scheifele DW, Ochnio JJ. The Immunological Basis for Immunization Series. Module 2: Diphtheria Update 2009. Immunization, 
Vaccines and Biologicals. Geneva: World Health Organization, 2009. Available at: 
whqlibdoc.who.int/publications/2009/9789241597869_eng.pdf  
[3] Rappuoli R. New and improved vaccines against diphtheria and tetanus. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, editors. 
New Generation Vaccines, 2nd Edition. New York: Marcel Dekker, 1997: 417-36. 
[4] Coombes L, Stickings P, Tierney R, Rigsby P, Sesardic D. Development and use of a novel in vitro assay for testing of diphtheria 
toxoid in combination vaccines. J Immunol Methods 2009;350:142-9. 
212  Paul Stickings et al. / Procedia in Vaccinology 5 (2011) 200 – 212 P Stickings et al. / Procedia in Vaccinology 00 (2011) 000–000  
[5] World Health Organization. Requirements for diphtheria, tetanus, pertussis and combined vaccines. In: WHO Expert Committee on 
Biological Standardization. Fortieth Report. Geneva, World Heatlh Organization, 1990, Annex 2 (WHO Technical Report Series, No. 
800). Available at: http://www.who.int/biologicals/publications/trs/areas/vaccines/dtp/en/index.html 
[6] World Health Organization. Recommendations for diphtheria, tetanus, pertussis and combined vaccines (Amendments 2003). In: 
WHO Expert Committee on Biological Standardization. Fifty-fourth Report. Geneva, World Health Organization, 2005, Annex 5 
(WHO Technical Report Series, No. 927). Available at: 
http://www.who.int/biologicals/publications/trs/areas/vaccines/dtp/en/index.html 
[7] Assay of diphtheria vaccine (adsorbed). General Chapter 2.7.6. In: European Pharmacopoeia, 6th edition. Strasbourg: Directorate for 
the Quality of Medicines & HealthCare of the Council of Europe (EDQM), 2008. 
[8] Assay of tetanus vaccine (adsorbed). General Chapter 2.7.8. In: European Pharmacopoeia, 6th edition. Strasbourg: Directorate for the 
Quality of Medicines & HealthCare of the Council of Europe (EDQM), 2008. 
[9] Sesardic D, Winsnes R, Rigsby P, Tierney R, Gaines-Das R. Calibration of replacement International Standard and European 
Pharmacopoeia Biological Reference Preparation for tetanus toxoid, adsorbed. Biologicals 2002;30:49-68. 
[10] Stickings P, Rigsby P, Coombes L, Malik K, Matejtschuk P, Sesardic D. Collaborative study for the calibration of a replacement 
International Standard for diphtheria toxoid adsorbed. Biologicals 2010;38(5):529-38. 
[11] Winsnes R, Hendriksen C, Sesardic D, Akkermans A, Daas A. Serological assays as alternatives to the Ph Eur challenge test for batch 
release of tetanus vaccines for human use. Dev Biol Stand 1999;101:277-88. 
[12] Winsnes R, Sesardic D, Daas A, Rigsby P. A Vero cell method for potency testing of diphtheria vaccines. Dev Biol (Basel) 
2002;111:141-8. 
[13] Winsnes R, Hendriksen C. Collaborative study for the validation of serological methods for potency testing of tetanus toxoid vaccines 
for human use - summary of all three phases. Pharmeuropa Spec Issue Biol 2002; 2:1-92. 
[14] Winsnes R, Sesardic D, Daas A, Behr-Gross ME. Collaborative study for the validation of serological methods for potency testing of 
diphtheria toxoid vaccines – part 1. Pharmeuropa Bio 2004;2003(2):35-68. 
[15] Sesardic D, Winsnes R, Rigsby P, Behr-Gross ME. Collaborative study for the validation of serological methods for potency testing of 
diphtheria toxoid vaccines – extended study: correlation of serology with in vivo toxin neutralisation. Pharmeuropa Bio 
2004;2003(2):69-76. 
[16] Winsnes R, Sesardic D, Daas A, Behr-Gross ME. Collaborative study for the validation of serological methods for potency testing of 
diphtheria toxoid vaccines (part 2). Pharmeuropa Bio 2006; 2006(1):73-88. 
[17] Gupta RK, Anderson R, Cecchini D, Rost B, Griffin P Jr, Benscoter K, Xu J, Montanez-Ortiz L, Siber GR. Development of a guinea-
pig model for potency/immunogenicity evaluation of diphtheria, tetanus, acellular pertussis (DTaP) and Haemophilus influenzae type 
b polysaccharide conjugate vaccines. Dev Biol Stand 1996;86:283-96.  
[18] Winsnes R, Sesardic D, Daas A, Terao E, Behr-Gross ME. Collaborative study on a guinea pig serological method for the assay of 
acellular pertussis vaccines. Pharmeur Bio Sci Notes 2009;2009(1):27-40. 
[19] Redhead K, Sesardic D, Yost SE, Attwell A-M, Watkins J, Hoy CS, Plumb JE, Corbel MJ. Combination of DTP and Haemophilus 
influenzae type b conjugate vaccines can affect laboratory evaluation of potency and immunogenicity. Biologicals 1994;22(4):339-45. 
[20] Gupta RK, Anderson R, Cecchini D, Rost B, Xu J, Gendreau K, Saroff DL, Marchant C, Siber GR. Evaluation of a guinea pig model 
to assess interference in the immunogenicity of different components of a combination vaccine comprising diphtheria, tetanus and 
acellular pertussis (DTaP) vaccine and Haemophilus influenzae type b capsular polysaccharide conjugate vaccine. Biologicals 
1999;27(2): 167-76. 
[21] Kondo S, Kameyama S, Murata R. Standardization and control of toxoid components in the combined vaccine (DPT). Jpn J Med Sci 
Biol 1974;27(6):315-19.  
[22] Sesardic D, Dawes CS, McLellan K, Durrani Z, Yost SE, Corbel MJ. Non-pertussis components of combination vaccines: problems 
with potency testing. Biologicals 1999;27(2):177-81. 
[23] Hendriksen CFM, Garthoff B, Aggerbeck H, Bruckner L, Castle P, Cussler K, Dobbelaer R, van de Donk H, van der Gund J, 
Lefrancois S, Milstien J, Minor PD, Maugeot H, Rombaut B, Ronneberger HD, Spieser J-M, Stolp R, Straughan DW, Tollis M, 
Zigtermans G. Alternatives to animal testing in the quality control of immunobiologicals: current status and future prospects. The 
report and recommendations of ECVAM Workshop 4. Altern Lab Anim 1994;22:420-34. 
[24] Miyamura K, Nishio S, Ito A, Murata R, Kono R. Micro cell culture method for determination of diphtheria toxin and antitoxin titres 
using VERO cells. I. Studies on factors affecting the toxin and antitoxin titration. J Biol Stand 1974;2(3):189-201. 
[25] Aggerbeck H, Heron I. Improvement of a Vero cell assay to determine diphtheria antitoxin content in sera. Biologicals 1991;19(2):71-
6. 
[26] Statistical analysis of results of biological assays and tests. General Chapter 5.3. In: European Pharmacopoeia, 6th edition. Strasbourg: 
Directorate for the Quality of Medicines & HealthCare of the Council of Europe (EDQM), 2008. 
[27] Dobbelaer R, Knight P, Lyng J. Use and validation of a single vaccine dilution assay for testing the potency of diphtheria, tetanus and 
combined vaccines. In: WHO Manual of laboratory methods: For testing of vaccines used in the WHO Expanded Programme on 
Immunization. Geneva: World Health Organization, 1997:162-74.  
[28] Hardegree MC, Pittman M, Maloney CJ. Influence of mouse strain on the assayed potency (unitage) of tetanus toxoid. Appl Microbiol 
1972;24(1):120-6. 
 
